- Markets
- Healthcare
- MERCURYLAB
MERCURYLAB
New to Zerodha? Sign-up for free.
New to Zerodha? Sign-up for free.
-
Share Price
-
Financials
-
Revenue mix
-
Shareholdings
-
Peers
-
Forensics
- 5D
- 1M
- 6M
- YTD
- 1Y
- 5Y
- MAX
This data is currently unavailable for this company.
-
Summary
-
Profit & Loss
-
Balance sheet
-
Cashflow
This data is currently unavailable for this company.
(In Cr.) |
---|
(In Cr.) | ||||
---|---|---|---|---|
This data is currently unavailable for this company. |
(In %) |
---|
(In Cr.) |
---|
Financial Year (In Cr.) |
---|
-
Product wise
-
Location wise
Revenue Mix
This data is currently unavailable for this company.
Revenue Mix
This data is currently unavailable for this company.
Recent events
-
News
-
Corporate Actions
This data is currently unavailable for this company.
Events:
Dividend
Dividend
Dividend
Dividend
Dividend
Dividend
Dividend
Dividend
Dividend
Dividend
More Micro Cap Ideas
See similar 'Micro' cap companies with recent activity
Promoter Buying
Companies where the promoters are bullish
Capex
Companies investing on expansion
Superstar Investor
Companies where well known investors have invested
Popular questions
-
Business
-
Financials
-
Share Price
-
Shareholdings
What does Mercury Laboratories do?
Mercury Laboratories Ltd., established in 1952, is a leading pharmaceutical company specializing in gynecology, cardiovascular, multivitamins, antibiotics, pain management, and gastroenterology. Their focus is on mother and child care products.
Who are the competitors of Mercury Laboratories?
Mercury Laboratories major competitors are Bharat Immunological, Onyx Biotec, Samrat Pharmachem, Lasa Supergenerics, Makers Laboratories, Source Natural Foods, Parnax Lab. Market Cap of Mercury Laboratories is ₹106 Crs. While the median market cap of its peers are ₹105 Crs.
Is Mercury Laboratories financially stable compared to its competitors?
Mercury Laboratories seems to be financially stable compared to its competitors. The probability of it going bankrupt or facing a financial crunch seem to be lower than its immediate competitors.
Does Mercury Laboratories pay decent dividends?
The company seems to be paying a very low dividend. Investors need to see where the company is allocating its profits. Mercury Laboratories latest dividend payout ratio is 7.43% and 3yr average dividend payout ratio is 8.92%
How has Mercury Laboratories allocated its funds?
Companies resources are allocated to majorly unproductive assets like Capital Work in Progress
How strong is Mercury Laboratories balance sheet?
Balance sheet of Mercury Laboratories is strong. It shouldn't have solvency or liquidity issues.
Is the profitablity of Mercury Laboratories improving?
The profit is oscillating. The profit of Mercury Laboratories is ₹3.94 Crs for TTM, ₹5.65 Crs for Mar 2024 and ₹5.58 Crs for Mar 2023.
Is the debt of Mercury Laboratories increasing or decreasing?
Yes, The debt of Mercury Laboratories is increasing. Latest debt of Mercury Laboratories is ₹0.29 Crs as of Sep-24. This is greater than Mar-24 when it was -₹10.95 Crs.
Is Mercury Laboratories stock expensive?
Yes, Mercury Laboratories is expensive. Latest PE of Mercury Laboratories is 26.77, while 3 year average PE is 19.39. Also latest EV/EBITDA of Mercury Laboratories is 14.09 while 3yr average is 10.93.
Has the share price of Mercury Laboratories grown faster than its competition?
Mercury Laboratories has given better returns compared to its competitors. Mercury Laboratories has grown at ~11.73% over the last 7yrs while peers have grown at a median rate of 7.0%
Is the promoter bullish about Mercury Laboratories?
Promoters stake in the company seems stable, and we need to go through filings and allocation of resources to gauge promoter bullishness. Latest quarter promoter holding in Mercury Laboratories is 73.66% and last quarter promoter holding is 73.66%.
Are mutual funds buying/selling Mercury Laboratories?
There is Insufficient data to gauge this.